Report cover image

Anti-Ischemic Agents Market by Type (Antiplatelet Agents, Calcium Channel Blockers, Organic Nitrates), Indication (Angina Pectoris, Ischemic Stroke, Myocardial Infarction), Route of Administration, End-User - Global Forecast 2024-2030

Publisher 360iResearch
Published Jan 15, 2024
Length 184 Pages
SKU # IRE18418366

Description

Anti-Ischemic Agents Market by Type (Antiplatelet Agents, Calcium Channel Blockers, Organic Nitrates), Indication (Angina Pectoris, Ischemic Stroke, Myocardial Infarction), Route of Administration, End-User - Global Forecast 2024-2030


The Anti-Ischemic Agents Market size was estimated at USD 355.88 million in 2023 and expected to reach USD 378.99 million in 2024, at a CAGR 6.23% to reach USD 543.43 million by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Anti-Ischemic Agents Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Anti-Ischemic Agents Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Anti-Ischemic Agents Market, highlighting leading vendors and their innovative profiles. These include Alembic Pharmaceuticals Limited, AstraZeneca, Baxter, Inc., Bayer AG, Boehringer Ingelheim, Bristol Myers Squibb, Cipla Ltd., Dr Reddy's Laboratories Ltd., Eli Lily & Company, Eris Lifesciences Ltd., FDC Ltd., Glenmark Pharmaceuticals Ltd., Intas Pharmaceuticals Ltd., Ipca Laboratories Ltd., J B Chemicals and Pharmaceuticals Ltd., Lupin Ltd., Macleods Pharmaceuticals Pvt Ltd., Medley Pharmaceuticals Ltd., Micro Labs Ltd., Natco Pharma Ltd., Novartis AG, Pfizer, Inc., Torrent Pharmaceuticals Ltd., Troikaa Pharmaceuticals Ltd., and Zydus Lifesciences Ltd..

Market Segmentation & Coverage

This research report categorizes the Anti-Ischemic Agents Market to forecast the revenues and analyze trends in each of the following sub-markets:

Type

Antiplatelet Agents
  • Calcium Channel Blockers
  • Organic Nitrates
  • Potassium Channel Openers
  • β-Blockers
  • Indication

    Angina Pectoris
  • Ischemic Stroke
  • Myocardial Infarction
  • Peripheral Artery Diseases
  • Route of Administration

    Intravenous (IV)
  • Oral
  • Transdermal
  • End-User

    Ambulatory Care
  • Homecare
  • Hospitals
  • Region

    Americas

    Argentina
  • Brazil
  • Canada
  • Mexico
  • United States

    California
  • Florida
  • Illinois
  • New York
  • Ohio
  • Pennsylvania
  • Texas
  • Asia-Pacific

    Australia
  • China
  • India
  • Indonesia
  • Japan
  • Malaysia
  • Philippines
  • Singapore
  • South Korea
  • Taiwan
  • Thailand
  • Vietnam
  • Europe, Middle East & Africa

    Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom
    The report offers valuable insights on the following aspects:

    1. Market Penetration: It presents comprehensive information on the market provided by key players.
    2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
    3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
    4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
    5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
    The report addresses key questions such as:

    1. What is the market size and forecast of the Anti-Ischemic Agents Market?
    2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Anti-Ischemic Agents Market?
    3. What are the technology trends and regulatory frameworks in the Anti-Ischemic Agents Market?
    4. What is the market share of the leading vendors in the Anti-Ischemic Agents Market?
    5. Which modes and strategic moves are suitable for entering the Anti-Ischemic Agents Market?


    Note: PDF & Excel + Online Access - 1 Year

    • Table of Contents

    184 Pages
    1. Preface
    1.1. Objectives of the Study
    1.2. Market Segmentation & Coverage
    1.3. Years Considered for the Study
    1.4. Currency & Pricing
    1.5. Language
    1.6. Limitations
    1.7. Assumptions
    1.8. Stakeholders
    2. Research Methodology
    2.1. Define: Research Objective
    2.2. Determine: Research Design
    2.3. Prepare: Research Instrument
    2.4. Collect: Data Source
    2.5. Analyze: Data Interpretation
    2.6. Formulate: Data Verification
    2.7. Publish: Research Report
    2.8. Repeat: Report Update
    3. Executive Summary
    4. Market Overview
    4.1. Introduction
    4.2. Anti-Ischemic Agents Market, by Region
    5. Market Insights
    5.1. Market Dynamics
    5.1.1. Drivers
    5.1.1.1. Changing lifestyles and rising prevalence of ischemic conditions
    5.1.1.2. Increasing utilization of advanced diagnostic tools and techniques for ischemic conditions
    5.1.1.3. Surge in research activities for developing new anti-ischemic agents
    5.1.2. Restraints
    5.1.2.1. High cost of treatment
    5.1.3. Opportunities
    5.1.3.1. Ongoing innovations and investment in drug development activities
    5.1.3.2. Collaborative efforts among various stakeholders for clinical trials
    5.1.4. Challenges
    5.1.4.1. Associated side-effects and safety concerns
    5.2. Market Segmentation Analysis
    5.3. Market Trend Analysis
    5.4. Cumulative Impact of High Inflation
    5.5. Porter’s Five Forces Analysis
    5.5.1. Threat of New Entrants
    5.5.2. Threat of Substitutes
    5.5.3. Bargaining Power of Customers
    5.5.4. Bargaining Power of Suppliers
    5.5.5. Industry Rivalry
    5.6. Value Chain & Critical Path Analysis
    5.7. Regulatory Framework
    6. Anti-Ischemic Agents Market, by Type
    6.1. Introduction
    6.2. Antiplatelet Agents
    6.3. Calcium Channel Blockers
    6.4. Organic Nitrates
    6.5. Potassium Channel Openers
    6.6. β-Blockers
    7. Anti-Ischemic Agents Market, by Indication
    7.1. Introduction
    7.2. Angina Pectoris
    7.3. Ischemic Stroke
    7.4. Myocardial Infarction
    7.5. Peripheral Artery Diseases
    8. Anti-Ischemic Agents Market, by Route of Administration
    8.1. Introduction
    8.2. Intravenous (IV)
    8.3. Oral
    8.4. Transdermal
    9. Anti-Ischemic Agents Market, by End-User
    9.1. Introduction
    9.2. Ambulatory Care
    9.3. Homecare
    9.4. Hospitals
    10. Americas Anti-Ischemic Agents Market
    10.1. Introduction
    10.2. Argentina
    10.3. Brazil
    10.4. Canada
    10.5. Mexico
    10.6. United States
    11. Asia-Pacific Anti-Ischemic Agents Market
    11.1. Introduction
    11.2. Australia
    11.3. China
    11.4. India
    11.5. Indonesia
    11.6. Japan
    11.7. Malaysia
    11.8. Philippines
    11.9. Singapore
    11.10. South Korea
    11.11. Taiwan
    11.12. Thailand
    11.13. Vietnam
    12. Europe, Middle East & Africa Anti-Ischemic Agents Market
    12.1. Introduction
    12.2. Denmark
    12.3. Egypt
    12.4. Finland
    12.5. France
    12.6. Germany
    12.7. Israel
    12.8. Italy
    12.9. Netherlands
    12.10. Nigeria
    12.11. Norway
    12.12. Poland
    12.13. Qatar
    12.14. Russia
    12.15. Saudi Arabia
    12.16. South Africa
    12.17. Spain
    12.18. Sweden
    12.19. Switzerland
    12.20. Turkey
    12.21. United Arab Emirates
    12.22. United Kingdom
    13. Competitive Landscape
    13.1. FPNV Positioning Matrix
    13.2. Market Share Analysis, By Key Player
    13.3. Competitive Scenario Analysis, By Key Player
    14. Competitive Portfolio
    14.1. Key Company Profiles
    14.1.1. Alembic Pharmaceuticals Limited
    14.1.2. AstraZeneca
    14.1.3. Baxter, Inc.
    14.1.4. Bayer AG
    14.1.5. Boehringer Ingelheim
    14.1.6. Bristol Myers Squibb
    14.1.7. Cipla Ltd.
    14.1.8. Dr Reddy's Laboratories Ltd.
    14.1.9. Eli Lily & Company
    14.1.10. Eris Lifesciences Ltd.
    14.1.11. FDC Ltd.
    14.1.12. Glenmark Pharmaceuticals Ltd.
    14.1.13. Intas Pharmaceuticals Ltd.
    14.1.14. Ipca Laboratories Ltd.
    14.1.15. J B Chemicals and Pharmaceuticals Ltd.
    14.1.16. Lupin Ltd.
    14.1.17. Macleods Pharmaceuticals Pvt Ltd.
    14.1.18. Medley Pharmaceuticals Ltd.
    14.1.19. Micro Labs Ltd.
    14.1.20. Natco Pharma Ltd.
    14.1.21. Novartis AG
    14.1.22. Pfizer, Inc.
    14.1.23. Torrent Pharmaceuticals Ltd.
    14.1.24. Troikaa Pharmaceuticals Ltd.
    14.1.25. Zydus Lifesciences Ltd.
    14.2. Key Product Portfolio
    15. Appendix
    15.1. Discussion Guide
    15.2. License & Pricing
    FIGURE 1. ANTI-ISCHEMIC AGENTS MARKET RESEARCH PROCESS
    FIGURE 2. ANTI-ISCHEMIC AGENTS MARKET SIZE, 2023 VS 2030
    FIGURE 3. ANTI-ISCHEMIC AGENTS MARKET SIZE, 2018-2030 (USD MILLION)
    FIGURE 4. ANTI-ISCHEMIC AGENTS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
    FIGURE 5. ANTI-ISCHEMIC AGENTS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 6. ANTI-ISCHEMIC AGENTS MARKET DYNAMICS
    FIGURE 7. ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
    FIGURE 8. ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 9. ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
    FIGURE 10. ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 11. ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
    FIGURE 12. ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 13. ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
    FIGURE 14. ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 15. AMERICAS ANTI-ISCHEMIC AGENTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
    FIGURE 16. AMERICAS ANTI-ISCHEMIC AGENTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 17. UNITED STATES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
    FIGURE 18. UNITED STATES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 19. ASIA-PACIFIC ANTI-ISCHEMIC AGENTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
    FIGURE 20. ASIA-PACIFIC ANTI-ISCHEMIC AGENTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
    FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 23. ANTI-ISCHEMIC AGENTS MARKET, FPNV POSITIONING MATRIX, 2023
    FIGURE 24. ANTI-ISCHEMIC AGENTS MARKET SHARE, BY KEY PLAYER, 2023

    Pricing

    Currency Rates
    How Do Licenses Work?

    How Do Licenses Work?

    The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

    • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

    • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

    • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

    • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

    • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

    License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

    Head shot

    Questions or Comments?

    Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
    Chat Now
    Contact Us